

# Sascha A Tuchman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8190739/publications.pdf>

Version: 2024-02-01

40  
papers

769  
citations

623734

14  
h-index

526287

27  
g-index

45  
all docs

45  
docs citations

45  
times ranked

1156  
citing authors

#	ARTICLE	IF	CITATIONS
1	Age-Specific Differences in Oncogenic Pathway Dysregulation in Patients With Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2009, 27, 5580-5586.	1.6	90
2	Gene Expression Signatures, Clinicopathological Features, and Individualized Therapy in Breast Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2008, 299, 1574.	7.4	89
3	Gene Expression Profiles of Tumor Biology Provide a Novel Approach to Prognosis and May Guide the Selection of Therapeutic Targets in Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2009, 27, 4197-4203.	1.6	69
4	Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. <i>Blood Cancer Journal</i> , 2021, 11, 192.	6.2	62
5	Multiple Myeloma in the Older Adult: Better Prospects, More Challenges. <i>Journal of Clinical Oncology</i> , 2014, 32, 2531-2540.	1.6	61
6	Characterizing the developmental pathways <i>TTF-1</i> , <i>NKX2-8</i> , and <i>PAX9</i> in lung cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 5312-5317.	7.1	50
7	Geriatric Assessment in Older Adults with Multiple Myeloma. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 987-991.	2.6	42
8	Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma. <i>Journal of Clinical Apheresis</i> , 2015, 30, 176-182.	1.3	40
9	Non-secretory multiple myeloma: from biology to clinical management. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 7583-7590.	2.0	39
10	Reference intervals and diagnostic ranges for serum free $\kappa$ and free $\lambda$ immunoglobulin light chains vary by instrument platform: Implications for classification of patient results in a multi-center study. <i>Clinical Biochemistry</i> , 2018, 58, 100-107.	1.9	25
11	Comparison of Retroviral Transduction Efficiency in CD34+ Cells Derived from Bone Marrow versus G-CSF-Mobilized or G-CSF Plus Stem Cell Factor-Mobilized Peripheral Blood in Nonhuman Primates. <i>Stem Cells</i> , 2004, 22, 1062-1069.	3.2	18
12	Characterizing the Clinical Relevance of an Embryonic Stem Cell Phenotype in Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2009, 15, 7553-7561.	7.0	18
13	What Is Multiple Myeloma?. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 497.	7.4	16
14	A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202). <i>American Journal of Hematology</i> , 2021, 96, 1595-1603.	4.1	15
15	Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma. <i>Leukemia</i> , 2021, 35, 3526-3533.	7.2	13
16	Geriatric-assessment-identified functional deficits among adults with multiple myeloma with normal performance status. <i>Journal of Geriatric Oncology</i> , 2022, 13, 182-189.	1.0	13
17	Phase II study of dose-attenuated bortezomib, cyclophosphamide and dexamethasone (VCD-Lite) in very old or otherwise toxicity-vulnerable adults with newly diagnosed multiple myeloma. <i>Journal of Geriatric Oncology</i> , 2017, 8, 165-169.	1.0	11
18	Phase 1 open-label study of panobinostat, lenalidomide, bortezomib+dexamethasone in relapsed and relapsed/refractory multiple myeloma. <i>Blood Cancer Journal</i> , 2021, 11, 20.	6.2	11

#	ARTICLE	IF	CITATIONS
19	Simplified frailty assessment tools: are we really capturing frailty or something else?. <i>Leukemia</i> , 2020, 34, 1967-1969.	7.2	11
20	HER-2/neu and CD117 (c-kit) overexpression in patients with pesticide exposure and extensive stage small cell lung carcinoma (ESSCLC). <i>Journal of Carcinogenesis</i> , 2005, 4, 8.	2.5	8
21	Once Weekly Oral Selinexor, Pomalidomide, and Dexamethasone in Relapsed Refractory Multiple Myeloma. <i>Blood</i> , 2021, 138, 2748-2748.	1.4	8
22	Lenalidomide before and after Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma. <i>Advances in Hematology</i> , 2012, 2012, 1-8.	1.0	5
23	Efficacy and safety of high-dose chemotherapy with autologous stem cell transplantation in senior versus younger adults with newly diagnosed multiple myeloma. <i>Hematological Oncology</i> , 2017, 35, 752-759.	1.7	5
24	A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma. <i>Blood Cancer Journal</i> , 2021, 11, 149.	6.2	5
25	Physical Function, Psychosocial Status, and Symptom Burden Among Adults with Plasma Cell Disorders and Associations with Quality of Life. <i>Oncologist</i> , 2022, 27, 694-702.	3.7	5
26	Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma in Older Adults. <i>Clinics in Geriatric Medicine</i> , 2016, 32, 191-205.	2.6	4
27	High-Risk Multiple Myeloma: Does it Still Exist?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, S70-S76.	0.4	3
28	Thrombosis in the modern era of multiple myeloma. <i>Blood</i> , 2020, 136, 1019-1021.	1.4	3
29	Selinexor-Based Regimens in Patients with Multiple Myeloma after Prior Anti-B-Cell Maturation Antigen Treatment. <i>Blood</i> , 2021, 138, 2751-2751.	1.4	3
30	A comparison of response in the presence or absence of a delay in induction therapy with bortezomib, lenalidomide, and dexamethasone. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 1692-1698.	0.9	2
31	Gamma Gap: A Point-of-Care Test That Correlates With Disease Burden and Treatment Response in Multiple Myeloma. <i>JCO Oncology Practice</i> , 2020, 16, e751-e757.	2.9	2
32	A Cross-Sectional Analysis of County-Level Social Vulnerability and Physical Frailty Among Adults with Hematological Malignancies. <i>Blood</i> , 2021, 138, 4130-4130.	1.4	2
33	Efficacy and Safety of Selinexor-Containing Regimens in Patients with Multiple Myeloma Previously Treated with Anti-CD38 Monoclonal Antibodies (±CD38 mAb). <i>Blood</i> , 2021, 138, 1651-1651.	1.4	2
34	A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (AFT-41). <i>Blood</i> , 2021, 138, 4776-4776.	1.4	1
35	Prevalence and clinical correlates of cognitive impairment in adults with plasma cell disorders. <i>Journal of Geriatric Oncology</i> , 2022, , .	1.0	1
36	Re: intrathecal vincristine as mentioned in "overview of recent trends in diagnosis and management of leptomeningeal multiple myeloma"™ by Yellu et al</i>.. <i>Hematological Oncology</i> , 2016, 34, 224-224.	1.7	0

#	ARTICLE	IF	CITATIONS
37	The Spectrum of Monoclonal Immunoglobulin-Associated Diseases. Hematology/Oncology Clinics of North America, 2020, 34, 997-1008.	2.2	0
38	Gene Expression Profiles with Signatures of Tumor Biology and Chemotherapy Sensitivity May Provide a Novel Approach to Maximize Response to Induction Therapy in Patients with Acute Myeloid Leukemia.. Blood, 2008, 112, 2252-2252.	1.4	0
39	Clinician Approaches to Myeloma in Academia and the Community : An in-Practice Qualitative Study. Blood, 2014, 124, 6010-6010.	1.4	0
40	Multiple Myeloma in Older Adults. , 2020, , 549-565.		0